company background image
TBPH

Theravance Biopharma NasdaqGM:TBPH Stock Report

Last Price

US$10.62

Market Cap

US$714.2m

7D

-3.4%

1Y

15.9%

Updated

31 Jan, 2023

Data

Company Financials +

Theravance Biopharma, Inc.

NasdaqGM:TBPH Stock Report

Mkt Cap: US$714.2m

TBPH Stock Overview

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia.

TBPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Theravance Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Theravance Biopharma
Historical stock prices
Current Share PriceUS$10.62
52 Week HighUS$11.83
52 Week LowUS$7.53
Beta0.53
1 Month Change-5.35%
3 Month Change10.05%
1 Year Change15.94%
3 Year Change-64.60%
5 Year Change-56.55%
Change since IPO-53.75%

Recent News & Updates

Recent updates

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Apr 21
Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Mar 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Mar 08
Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Would Shareholders Who Purchased Theravance Biopharma's (NASDAQ:TBPH) Stock Year Be Happy With The Share price Today?

Feb 01
Would Shareholders Who Purchased Theravance Biopharma's (NASDAQ:TBPH) Stock Year Be Happy With The Share price Today?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Dec 09
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Shareholder Returns

TBPHUS PharmaceuticalsUS Market
7D-3.4%-2.1%0.2%
1Y15.9%2.8%-13.6%

Return vs Industry: TBPH exceeded the US Pharmaceuticals industry which returned 4.5% over the past year.

Return vs Market: TBPH exceeded the US Market which returned -9.2% over the past year.

Price Volatility

Is TBPH's price volatile compared to industry and market?
TBPH volatility
TBPH Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: TBPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: TBPH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013159Rick Winninghamhttps://www.theravance.com

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease.

Theravance Biopharma, Inc. Fundamentals Summary

How do Theravance Biopharma's earnings and revenue compare to its market cap?
TBPH fundamental statistics
Market CapUS$714.19m
Earnings (TTM)-US$70.74m
Revenue (TTM)US$51.64m

13.8x

P/S Ratio

-10.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TBPH income statement (TTM)
RevenueUS$51.64m
Cost of RevenueUS$91.40m
Gross Profit-US$39.76m
Other ExpensesUS$30.98m
Earnings-US$70.74m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.05
Gross Margin-76.98%
Net Profit Margin-136.98%
Debt/Equity Ratio0%

How did TBPH perform over the long term?

See historical performance and comparison